Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 52
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

New molecular tools for precision medicine in pituitary neuroendocrine tumors

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Valassi, Elena|||0000-0002-3864-0105
  • Pons, Laura|||0000-0003-0784-4110
  • Carrato, Cristina|||0000-0002-1953-8287
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Precision, personalized, or individualized medicine in pituitary neuroendocrine tumors (PitNETs) has become a major topic in the last few years. It is based on the use of biomarkers that predictively segregate patients and give answers to clinically relevant questions that help us in the individualization of their management. It allows us to make early diagnosis, predict response to medical treatments, predict surgical outcomes and investigate new targets for therapeutic molecules. So far, substantial progress has been made in this field, although there are still not enough precise tools that can be implemented in clinical practice. One of the main reasons is the excess overlap among clustered patients, with an error probability that is not currently acceptable for clinical practice. This overlap is due to the high heterogeneity of PitNETs, which is too complex to be overcome by the classical biomarker investigation approach. A systems biology approach based on artificial intelligence techniques seems to be able to give answers to each patient individually by building mathematical models through the interaction of multiple factors, including those of omics sciences. Integrated studies of different molecular omics techniques, as well as radiomics and clinical data are necessary to understand the whole system and to finally achieve the key to obtain precise biomarkers and implement personalized medicine. In this review we have focused on describing the current advances in the area of PitNETs based on the omics sciences, that are clearly going to be the new tool for precision medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Personalized Medicine in Acromegaly, The ACROFAST Study, Medicina Personalizada en Acromegalia

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Sampedro Núñez, Miguel Antonio
  • Valassi, Elena|||0000-0002-3864-0105
  • Biagetti, Betina|||0000-0002-8837-4343
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Hernández García, Marta|||0000-0003-1237-298X
  • Martínez, Silvia
  • Carrato, Cristina|||0000-0002-1953-8287
  • Villar Taibo, Rocío
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Blanco Carrera, Concepción|||0000-0001-7171-9459
  • Simón-Muela, Inmaculada
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Xifra, Gemma
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pavón, Isabel
  • Rosado, José Antonio
  • García Centeno, Rogelio
  • Zavala, Roxana
  • Hanzu, Felicia A.|||0000-0002-2399-4023
  • Mora, Mireia|||0000-0002-5887-5016
  • Aulinas, Anna|||0000-0002-1205-7114
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Librizzi, Soledad
  • Calatayud, María|||0000-0002-6737-7289
  • de Miguel, Paz
  • Álvarez-Escolá, Cristina|||0000-0002-4684-1652
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Salinas, Isabel
  • Fajardo-Montañana, Carmen|||0000-0002-0784-0761
  • Cámara, Rosa|||0000-0002-3289-3400
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Jordà, Mireia|||0000-0003-3709-1850
  • Webb, S. M.|||0000-0001-7052-6436
  • Marazuela, Mónica|||0000-0003-1158-9618
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response. Objective:Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated. Methods: This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control. Results:Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P < .05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI, 1.30-4.80). Patients from the personalized arm were controlled in a shorter period of time (P = .01). Conclusion:Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unique Splicing of Lrp5 in the Brain, A New Player in Neurodevelopment and Brain Maturation

  • Luquero, Aureli|||0000-0002-1104-5963
  • Pimentel, Noelia
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Badimon, Lina|||0000-0002-9162-2459
  • Borrell-Pages, Maria|||0000-0002-1759-9756
Low-density lipoprotein receptor-related protein 5 (LRP5) is a constitutively expressed receptor with observed roles in bone homeostasis, retinal development, and cardiac metabolism. However, the function of LRP5 in the brain remains unexplored. This study investigates LRP5's role in the central nervous system by conducting an extensive analysis using RNA-seq tools and in silico assessments. Two protein-coding Lrp5 transcripts are expressed in mice: full-length Lrp5-201 and a truncated form encoded by Lrp5-202. Wt mice express Lrp5-201 in the liver and brain and do not express the truncated form. Lrp5 mice express Lrp5-202 in the liver and brain and do not express Lrp5-201 in the liver. Interestingly, Lrp5 mouse brains show full-length Lrp5-201 expression, suggesting that LRP5 has a role in preserving brain function during development. Functional gene enrichment analysis on RNA-seq unveils dysregulated expression of genes associated with neuronal differentiation and synapse formation in the brains of Lrp5 mice compared to Wt mice. Furthermore, Gene Set Enrichment Analysis highlights downregulated expression of genes involved in retinol and linoleic acid metabolism in Lrp5 mouse brains. Tissue-specific alternative splicing of Lrp5 in Lrp5 mice supports that the expression of LRP5 in the brain is needed for the correct synthesis of vitamins and fatty acids, and it is indispensable for correct brain development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors

  • Martínez-Hernández, Rebeca
  • Serrano-Somavilla, Ana
  • Fernández-Contreras, Raul
  • Sanchez-Guerrero, Cristina
  • Sánchez de la Blanca, Nuria
  • Sacristán-Gómez, Pedro
  • Sebastian-Valles, Fernando|||0000-0002-4127-0483
  • Sampedro Núñez, Miguel Antonio
  • Fraga, Javier
  • Calatayud, María|||0000-0002-6737-7289
  • Vicente, Almudena
  • García-de-Casasola, G.|||0000-0002-5171-7373
  • Sanz-García, Ancor
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Ruz-Caracuel, Ignacio|||0000-0002-2298-4683
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Marazuela, Mónica|||0000-0003-1158-9618
Pituitary neuroendocrine tumors (PitNETs) account for approximately 15% of all intracranial neoplasms. Although they usually appear to be benign, some tumors display worse behavior, displaying rapid growth, invasion, refractoriness to treatment, and recurrence. Increasing evidence supports the role of primary cilia (PC) in regulating cancer development. Here, we showed that PC are significantly increased in PitNETs and are associated with increased tumor invasion and recurrence. Serial electron micrographs of PITNETs demonstrated different ciliation phenotypes (dot-like versus normal-like cilia) that represented PC at different stages of ciliogenesis. Molecular findings demonstrated that 123 ciliary-associated genes (eg, doublecortin domain containing protein 2, Sintaxin-3, and centriolar coiled-coil protein 110) were dysregulated in PitNETs, representing the upregulation of markers at different stages of intracellular ciliogenesis. Our results demonstrate, for the first time, that ciliogenesis is increased in PitNETs, suggesting that this process might be used as a potential target for therapy in the future.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acromegaly facial changes analysis using last generation artificial intelligence methodology, the AcroFace system

  • Rashwan, Hatem A.
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Ruiz, Sabina
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Asensio-Wandosell, Diego|||0009-0005-6439-8518
  • Martínez Momblán, Ma. Antonia|||0000-0002-5364-5270
  • Vázquez, Federico|||0000-0001-6493-2374
  • Salinas, Isabel
  • Ciriza, Raquel
  • Jordà, Mireia|||0000-0003-3709-1850
  • Chanson, Philippe|||0000-0001-5096-5722
  • Valassi, Elena|||0000-0002-3864-0105
  • Abdelnasser, Mohamed
  • Puig, Domènec
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Purpose: To describe the development of the AcroFace system, an AI-based system for early detection of acromegaly, based on facial photographs analysis. Methods: Two types of features were explored: (1) the visual/texture of a set of 2D facial images, and (2) geometric information obtained from a reconstructed 3D model from a single image. We optimized acromegaly detection by integrating SVM for geometric features and CNNs for visual features, each chosen for their strength in processing distinct data types effectively. This combination enhances overall accuracy by leveraging SVM's capability to manage structured, quantitative data and CNNs' proficiency in interpreting complex image textures, thus providing a comprehensive analysis of both geometric alignment and textural anomalies. ResNet-50, VGG-16, MobileNet, Inception V3, DensNet121 and Xception models were trained with an expert endocrinologist-based score as a ground truth. Results: ResNet-50 model as a feature extractor and Support Vector Regression (SVR) with a linear kernel showed the best performance (accuracy δ1 of 75% and δ3 of 89%), followed by the VGG-16 as a feature extractor and SVR with a linear kernel. Geometric features yield less accurate results than visual ones. The validation cohort showed the following performance: precision 0.90, accuracy 0.93, F1-Score 0.92, sensitivity 0.93 and specificity 0.93. Conclusion: AcroFace system shows a good performance to discriminate acromegaly and non-acromegaly facial traits that may serve for the detection of acromegaly at an early stage as a screening procedure at a population level.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

  • Marazuela, Mónica|||0000-0003-1158-9618
  • Martínez-Hernández, Rebeca
  • Marques-Pamies, Manuel
  • Biagetti, Betina|||0000-0002-8837-4343
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Mies, Belén
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene|||0000-0003-1986-2965
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana|||0000-0001-7763-320X
  • D'Angelo, Emanuela|||0000-0002-6173-1806
  • Hardisson, David|||0000-0002-2183-3699
  • Vieites, Begoña
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Estévez-García, Purificación
  • Guerra, Eva|||0000-0003-1910-4451
  • Prat, Jaime|||0000-0002-9787-3304
  • Poveda, Andrés
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Palacios, José|||0000-0002-6730-5066
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quality of life and psychological status in people with acromegaly in relation to disease-related facial changes

  • Martínez Momblán, Ma. Antonia|||0000-0002-5364-5270
  • Alonso Fernández, Sergio|||0000-0001-6969-9380
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Salinas, Isabel
  • Vázquez, Federico|||0000-0001-6493-2374
  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Asensio-Wandosell, Diego|||0009-0005-6439-8518
  • Ciriza, Raquel
  • Santos, Alicia|||0000-0002-2179-6189
  • Valassi, Elena|||0000-0002-3864-0105
  • Webb, S. M.|||0000-0001-7052-6436
  • Puig Domingo, Manuel|||0000-0002-6744-7195
The diagnosis of acromegaly is often delayed, leading to facial disfigurements that persist despite endocrine cure. We aimed to study the relationship between facial modifications, quality of life (QoL) and psychological status in patients with acromegaly. Methods: Sixty-five patients in remission or with hormonal disease control participated (29 women and 36 men; mean age 57.4 ± 13.5 years). The following variables were assessed: i) sex; ii) QoL by AcroQoL; iii) anxiety level with the STAI questionnaire; iv) self-esteem by the Rosenberg scale; and v) facial acromegaly phenotypical changes evaluated from face photographs by eight experienced endocrinologists using a Likert scale. Results: The global AcroQoL score for the whole cohort showed mid-range values, with higher median values for men (72.3 vs 56.6, P = 0.022) mostly dependent on the physical domain, which was higher for men (59.0 vs 34.9, P = 0.006), rather than the psychological domain (65.7 vs 54.5, P = 0.069). Anxiety scores were also higher for women (7.3 vs 5.9, P = 0.009). Self-esteem state was high (2.7 ± 0.6 for a maximal value of 3) for the whole cohort without sex differences. A higher difference in the global phenotypic facial acromegaly features score from baseline and post-diagnosis was associated with a lower value on QoL mostly in women (14.38 95% CI 5.25 to 23.52; P-value = 0.005), with less effect in men (6.31 95% CI 0.61 to 13.22; Pvalue = 0.070). Conclusion: In controlled acromegaly, QoL is relatively preserved in both genders, although men have higher general and physical domain scores and lower anxiety status. Facial changes intensity negatively impacted QoL mostly in women.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Grinyó-Escuer, Ariadna|||0000-0003-0185-2734
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Rius-Ruiz, Irene
  • Bort-Brusca, Marta
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Maqueda-Marcos, Susana
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Gago, Judit
  • Nogales, Vanesa
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Soucek, Laura|||0000-0002-4750-7971
  • Braña, Irene|||0000-0002-1068-9601
  • Galvao, Vladimir
  • Martín-Lluesma, Silvia|||0000-0001-7491-1876
  • Moessner, Ekkehard
  • Klein, Christian|||0000-0001-7594-7280
  • Garralda, Elena|||0000-0002-4412-7842
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chimeric antigen receptor T (CAR-T) cell therapy is efficient in certain haematologic malignancies, but clinical success in solid tumours has been hampered by scarcity of tumour-specific antigens. Here authors show that combination therapy using CAR T cells targeting p95HER2 and bispecific antibodies against HER2 and CD3 consistently leads to complete regression in HER2-positive, patient-derived xenografts tumours in mouse models.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Does Platelet Transcriptome Dysregulation Across the Lewy Body Continuum Mirror Neuronal Dysfunction?

  • Arnaldo, Laura|||0000-0003-1654-0573
  • Mena, Jorge|||0009-0001-4524-205X
  • Adamuz , David|||0009-0008-0326-5991
  • Menéndez Albarracín, Alex|||0009-0001-0472-6402
  • Serradell, Mònica|||0000-0002-2954-3020
  • Samaniego-Toro, Daniela|||0000-0001-8362-0747
  • Gaig, Carles|||0000-0002-7113-8125
  • Ispierto, Lourdes
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Iranzo, Alex|||0000-0002-5618-8271
  • Aarsland, Dag|||0000-0001-6314-216X
  • Pastor, Pau|||0000-0002-7493-8777
  • Beyer, Katrin|||0000-0001-8905-1514
Platelets are increasingly recognized as multifunctional cells with roles extending beyond hemostasis to immune regulation, inflammation, and neurodegeneration. Here, we performed RNA-Seq profiling of platelets from patients with idiopathic REM sleep behavior disorder (IRBD), dementia with Lewy bodies (DLB), Parkinson disease (PD), Alzheimer disease (AD), and healthy controls (CTRLs) to explore disease-specific transcriptomic signatures. Across all groups, the RNA class distribution was similar, dominated by mRNAs (78-80%) and long non-coding RNAs (lncRNAs; 15-16%). DLB platelets displayed a reduced proportion of lncRNAs, suggesting an impaired RNA regulation, whereas IRBD concentrated the highest number of disease-specific lncRNAs, half of which were Y-linked, consistent with the male predominance observed in alpha-synucleinopathies. Differential expression analysis (DEA) revealed extensive transcriptomic remodeling in IRBD and DLB, particularly affecting RNA processing, cytoskeletal organization, and platelet activation pathways, while PD and AD showed minimal changes. These findings suggest a progressive impairment of platelet activation and signaling across the DLB continuum, potentially mirroring neuronal dysfunction. The limited transcriptional deregulation in PD may reflect its pronounced biological heterogeneity, consistent with recent multidimensional disease models. Overall, our study highlights platelets as accessible indicators of early and disease-stage-specific molecular alterations in α-synucleinopathies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia

  • Minguez, B.|||0000-0002-7699-3972
  • Paredes-Fuentes, Abraham J.|||0000-0002-7163-2385
  • Oliva, C.
  • Rodriguez-Gonzalez, H.
  • Santos Ocaña, Carlos|||0000-0002-2379-796X
  • Artuch, R.|||0000-0002-3422-9685
  • Santos, Mariela de los
  • Garcia-Volpe, Camila
  • Molera Busoms, Cristina
  • Arias, Angela
  • Yubero, Délia
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Meavilla, Silvia
Coenzyme Q10 (CoQ) is a ubiquitous lipid with different biological functions. In blood, there is a close relationship between CoQ status and cholesterol, which strongly supports the study of both molecules simultaneously. The objective of this study was to evaluate plasma CoQ, lipoprotein concentrations and CoQ/Chol ratio in a cohort of paediatric patients with different types of dyslipidaemias. A total of 60 paediatric patients were recruited (age range: 7 months-18 years), including 52 with different types of hypercholesterolemia, 2 with isolated hypertriglyceridemia and 6 with hypobetalipoproteinemia. Plasma CoQ was analysed by HPLC with electrochemical detection, and lipoprotein and cholesterol concentrations by standard automated methods. The lowest CoQ values were detected in patients with hypobetalipoproteinemia and in two cases of liver cirrhosis. Mean CoQ values were significantly higher in hypercholesterolemic patients compared to controls (average values 1.07 µmol/L and 0.63 µmol/L) while the CoQ/cholesterol ratio did not show differences (170 vs. 163, respectively). Mean CoQ values were significantly lower in the group of patients with hypobetalipoproteinemia compared to controls (mean CoQ values of 0.22 µmol/L vs. 0.63 µmol/L, respectively), while those of CoQ/cholesterol did not show differences. Pearson's correlation test showed a positive correlation between the CoQ and cholesterol values (r = 0.565, p < 0.001) and between the CoQ and the LDL cholesterol values (r = 0.610, p < 0.001). Our results suggest that it is advisable to analyse plasma CoQ and cholesterol concentrations in patients with hypobetalipoproteinemia and hypercholesterolemia associated with liver damage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer

  • Terradas, Mariona|||0000-0001-7813-1172
  • Mur, Pilar
  • Bousquets-Muñoz, Pablo
  • Puente, Xose S.|||0000-0001-9525-1483
  • Nielsen, Maartje|||0000-0002-5351-1870
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Valle, Laura|||0000-0003-0371-0844
  • Morón-Duran, Francisco D.
  • Mengod, Pol
  • Löffler, Chiara M.L.
  • Helderman, Noah C.
  • Terlouw, Diantha
  • Sanjuán, Xavier
  • Viana-Errasti, Julen
  • Capellá, Gabriel
  • van Wezel, Tom
  • Kather, Jakob Nikolas
Background: Constitutional primary monoallelic promoter methylation of hereditary cancer genes, although rare, may explain early-onset cancers without family history. Also, promoter methylation of a hereditary cancer gene secondary to a genetic alteration in a methylation regulatory region can cause a hereditary cancer syndrome. This study investigates constitutional promoter methylation as mechanism of inactivation of cancer predisposition genes in genetically unsolved familial and/or early-onset colorectal cancer (CRC) patients. Results: Bisulfite-treated peripheral blood DNA from 46 early-onset/familial CRC patients was analyzed using the Illumina Infinium MethylationEPIC BeadChip. One early-onset CRC patient exhibited constitutional, likely monoallelic, methylation of CpG island 102 in LTBP4, a gene involved in TGF-β signaling. Somatic methylation of this CpG island is common in CRC, and correlates with LTBP4 downregulation. LTBP4 double knockout mice develop colorectal adenomas and carcinomas, supporting the role of this gene in CRC predisposition. No additional cases with constitutional LTBP4 CpG island 102 methylation or enrichment of deleterious LTBP4 variants in CRC patients compared to controls were found. Another early-onset CRC patient exhibited mosaic BRCA1 promoter methylation, typically associated with increased breast and ovarian cancer risk. No somatic second hit in BRCA1 was detected in the patient's tumor, and homologous recombination deficiency-associated features were inconclusive. Conclusions: Our findings suggest that constitutional methylation of LTBP4 CpG island 102 may be associated with increased CRC risk. Identification of additional cases is needed to confirm the existence of a novel CRC predisposition syndrome driven by epigenetic inactivation of LTBP4, potentially also linked to other clinical phenotypes associated with LTBP4 deficiency, such as pulmonary emphysema. Whether constitutional BRCA1 methylation contributes to CRC risk remains to be determined.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of the new EASO obesity definition on the detection of atheromatosis in subjects with low-to-moderate cardiovascular risk

  • León-Mengíbar, Josep|||0000-0002-5982-3461
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Torres, Gerard|||0000-0002-1417-7320
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castro-Boqué, Eva|||0000-0002-1013-0007
  • Fernández, Elvira|||0000-0001-5236-1762
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Bueno, Marta|||0000-0001-9488-4553
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Hernández García, Marta|||0000-0003-1237-298X
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
  • Lecube, Albert|||0000-0001-9684-0183
Traditional body mass index (BMI) does not adequately reflect adipose tissue distribution and associated cardiovascular (CV) risk. To improve risk stratification, the European Association for the Study of Obesity (EASO) proposes to extend the diagnosis of obesity to include individuals with a BMI of 25-30 kg/m², a waist-to-height ratio (WtHR) ≥0.5, and any obesity-related complication. To examine whether this new definition of obesity can better identify the presence of subclinical atheromatosis disease (SAD) in terms of arterial plaque burden compared to the classical BMI-based definition. A cross-sectional including 8,330 participants from the ILERVAS project (ClinicalTrials.gov Identifier: ), aged 45-70 years with low-to-moderate CV risk and no previous CV disease, was included. Obesity was classified using traditional (BMI ≥ 30 kg/m²) and new definitions. Atherosclerosis was assessed through Doppler ultrasound of carotid and femoral arteries. Logistic regression models adjusted for cardiovascular risk factors were used to evaluate associations between obesity definitions and SAD. The new definition increased obesity prevalence from 37.2% to 71.7%. It also revealed higher detection of atheromatous plaques (72.9% vs. 68.6%, p.
Repisalud
Other research product Plan de Gestión de Datos (DataManagementPlan)

Medicina Personalizada (MedPer) en la detección precoz del Deterioro Cognitivo (DC) preclínico (DENDRITE). Desarrollo de un modelo predictivo de riesgo. Plan de Gestión de Datos (PGD) v. 2.0

  • Instituto de Salud Carlos III. Unidad de Investigación en Cuidados de Salud (Investén-ISCIII)
  • Instituto de Investigación Biomédica de Salamanca (IBSAL)
  • CIBER de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III (CIBERFES, ISCIII)
  • Alonso-del-Cura, Olatz
Plan de Gestión de Datos del proyecto DENDRITE. El objetivo principal del proyecto MedPer_DC es obtener un modelo predictivo para la detección preclínica del deterioro cognitivo en población de 55-70 años de edad, permitiendo así la implantación efectiva de la Medicina Personalizada de Precisión en Atención Primaria. El estudio involucra la participación de 6 Comunidades Autónomas y 7 centros de Atención Primaria en diferentes ubicaciones geográficas. Es una cohorte observacional, multicéntrica y no intervencional con métodos mixtos convergentes. Se desarrollará combinando una fase cuantitativa observacional y prospectiva con una fase cualitativa que involucrará grupos de discusión. Durante el estudio se recogerán datos multi-ómicos (moleculares, proteómicos, genómicos), asistenciales, sociales, ambientales, de voz y de conducta (provenientes de monitorización activa y pasiva) junto con información clínica complementaria. Todos estos datos se analizarán mediante diversas técnicas de análisis basadas en Inteligencia Artificial y en modelos estadísticos para sintetizar un perfil clínico, genético y molecular, de comportamiento y voz, y determinar su potencial para converger en un modelo predictivo global de DC.
Repisalud
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

Early detection of cognitive impairment in primary care: a mixed-methods protocol integrating data from multiple sources (DENDRITE study)

  • Almeida-Parra, Ángeles
  • Ropero-Sánchez, Andrea
  • Zamora Romero, Javier
  • Docío-Fernández, Laura
  • Fatjó-Vilas Mestre, Mar
  • Campuzano Ruiz, Susana
  • Lozano González, Pilar
  • Alonso-del-Cura, Olatz
  • Montero Calle, Ana
  • Barderas Manchado, Rodrigo
  • Moreno-Casbas, Teresa
  • MedPer_DC Project Working Group
Globally, over half of cognitive impairment cases identified in population-based studies remain undetected, and up to 90% of mild cases go undiagnosed. This represents a major public health challenge with significant implications for ageing populations and health systems. The present protocol outlines the integration of clinical, multiomic, healthcare, social, environmental, voice, and behavioral data, using artificial intelligence and advance statistical modeling, to develop a predictive risk model for the preclinical detection of cognitive impairment in adults aged 55–70 years. This is an observational, multicenter, non-interventional study employing a convergent mixed-methods approach. The design combines a prospective quantitative phase with a qualitative one based on discussion groups. The study will be conducted across six Spanish regions and seven primary healthcare centers located in different geographic areas. Each center will recruit 150 cognitively unimpaired participants, resulting in a total sample of 1050 participants. In addition, a calibration group of 100 participants diagnosed with mild cognitive impairment will be included. This protocol has been developed in accordance with the STROBE guidelines to ensure methodological rigor, transparency, and reproducibility. This research aims to develop a simple, cost-effective, and actionable tool for early preclinical detection of individuals at risk of cognitive impairment, enabling its integration into primary care and supporting timely, targeted interventions. This approach has the potential to reduce diagnostic delays, optimize healthcare resources, and promote equitable access to timely interventions, ultimately improving population health and quality of life.
Repisalud
Publication Artículo científico (JournalArticle)

Identification and functional insights into new phage tail-like bacteriocins targeting as new antimicrobials.

  • Ibarguren-Quiles, Clara
  • Blasco, Lucía
  • López-Causape, Carla
  • Bleriot, Inés
  • Fernández-García, Laura
  • Arman, Lucia
  • Barrio-Pujante, Antonio
  • Ortiz-Cartagena, Concha
  • Aracil, Belen
  • Menéndez-Rodriguez, Olaya
  • Mariñas-Pardo, Luis
  • Cantón, Rafael
  • Oliver, Antonio
  • Tomás, María
The current health crisis caused by multidrug-resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as , lead to high rates of complications, particularly in compromised patients such as cystic fibrosis (CF) patients. The need to counteract and minimize the forecast future impact has led to the rescue of phage therapy. The use of bacteriophages has important advantages, including highly specific targeting, self-amplification at the infection site, minimal disruption of the microbiome, safety, and biocompatibility. However, the capacity of bacteria to escape these entities results in a form of resistance that compromises the effectiveness of the therapy. This involves the search for potential alternatives, such as the phage tail-like bacteriocins (PTLBs), also named as tailocins. These high-molecular-weight particles resemble the tail structure of bacteriophages and are characterized by the absence of genetic material, avoiding the development of resistance, one of the major handicaps associated with phage therapy. In this study, we detected 34 different PTLBs in 75 genomes, with different serotypes and sequence types, 11 of which were characterized as novel F-type PTLB subtypes (F13-F24). Furthermore, we report that four selected PTLBs (R1, F15, F19, and R3-F24) can deal with bacterial infection, with the R1 and the F15 PTLBs being the most efficient in clearing infection , yielding a survival rate of more than 75% in the larvae model. This reaffirms the potential of PTLBs to control infections, which can cause chronic infections in some patients, such as people with CF, due to its strong impact as a MDR bacterium.IMPORTANCEThe 75 genomes from people with cystic fibrosis in the study collection included at least one phage tail-like bacteriocins (PTLB) cluster. From the 34 different PTLBs detected in the study collection, 7 were R-type, 10 were complex (R- and F-type encoded), and 14 were F-type PTLBs. Eleven new F-type PTLBs were described in the collection under study. An association between the O-antigen present on the surface of the isolate and the encoded PTLB subtype was detected. The R1 and F15 PTLB subtypes display high antimicrobial activity both in vitro and in vivo (Galleria mellonella).
Repisalud
Publication Contribución de congreso (ConferenceOutput)

Cognitive Screening Tools in Spanish for Mild Cognitive Impairment: A Systematic Review and Meta-analysis, Herramientas de cribado cognitivo en español para el deterioro cognitivo leve: una revisión sistemática y metaanálisis

  • Barderas Manchado, Rodrigo
  • Ropero-Sánchez, Andrea
  • Escudero Pérez, Guillermo
  • Lozano González, Pilar
  • Alonso-del-Cura, Olatz
  • Camacho-Montaño, Lucia
  • Pascual García, Marcos
  • Sánchez Ruano, Raquel
  • Martín Saborido, Carlos
  • Moreno-Casbas, Teresa
Mild Cognitive Impairment (MCI) represents the earliest stage of a chronic and degenerative condition, often undetected, impacting individuals, families, and healthcare systems. Early identification is critical. This study evaluates the diagnostic accuracy of MCI screening tools in Spanish-speaking populations, aiming to enhance early detection, reduce misdiagnosis and underdiagnosis, and improve clinical outcomes. This systematic review stems from the Project Dendrite (PMP22/00084 - "Personalized Medicine in the Identification of Preclinical Cognitive Impairment: Development of a Predictive Risk Model") in which it was demonstrated that the five screening tests employed in the study (MMSE, MoCA, Fototest, MiniCog, T@M) lacked consistency and yielded variable results, even in the same participant. This finding highlights the need to evaluate the diagnostic accuracy of the screening tools and their applicability in early cognitive decline detection.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Reallocating time between 24-h movement behaviors for obesity management across the lifespan: a pooled data meta-analysis of more than 9800 participants from seven countries

  • Gába, Aleš
  • Hartwig, Timothy B.
  • Jašková, Paulína
  • Sanders, Taren
  • Dygrýn, Jan
  • Vencálek, Ondřej
  • Antczak, Devan
  • Conigrave, James
  • Parker, Phillip
  • Pozo Cruz, Borja del
  • Fairclough, Stuart J.
  • Halson, Shona
  • Hron, Karel
  • Noetel, Michael
  • Ávila-García, Manuel
  • Cabanas-Sánchez, Verónica
  • Cavero-Redondo, Iván
  • Curtis, Rachel G.
  • Costa, Bruno G. G. da
  • Pozo Cruz, Jesús del
  • García Hermoso, Antonio
  • Leahy, Angus A.
  • Lubans, David R.
  • Maher, Carol A.
  • Martínez-Gómez, David
  • Meredith-Jones, Kim
  • Redondo-Tébar, Andrés
  • Sabia, Séverine
  • Silva, Kelly S.
  • Skidmore, Paula
  • Villa González, Emilio
  • Yerramalla, Manasa S.
  • Lonsdale, Chris
Background: The distribution of time across physical activity, sedentary behaviors, and sleep appears to be essential for the management of obesity. However, the impact of reallocating time among these behaviors, collectively known as 24-h movement behaviors, remains underexplored. Objective: This study examines the theoretical effects of reallocating time between 24-h movement behaviors on obesity indicators across different age groups. Methods: We performed a pooled data meta-analysis of 9818 participants from 11 observational and experimental studies. To estimate the time spent in movement behaviors, we reprocessed and harmonized individual-level raw accelerometer-derived data. Isotemporal substitution models estimated theoretical changes in body mass index (BMI) and waist circumference (WC) associated with time reallocation between movement behaviors. We performed the analysis separately for children, adolescents, adults, and older adults. Results: Even minor reallocations of 10 min led to significant changes in obesity indicators, with pronounced effects observed when 30 min were reallocated. The most substantial adverse effects on BMI and WC occurred when moderate-to-vigorous physical activity (MVPA) was reallocated to other movement behaviors. For 30-min reallocations, the largest increase in BMI (or BMI z-score for children) occurred when MVPA was reallocated to light-intensity physical activity (LPA) in children (0.26 units, 95% confidence interval [CI] 0.15, 0.37) and to sedentary behavior (SB) in adults (0.72 kg/m2, 95% CI 0.47, 0.96) and older adults (0.73 kg/m2, 95% CI 0.59, 0.87). The largest increase in WC was observed when MVPA was substituted with LPA in adults (2.66 cm, 95% CI 1.42, 3.90) and with SB in older adults (2.43 cm, 95% CI 2.07, 2.79). Conversely, the highest magnitude of the decrease in obesity indicators was observed when SB was substituted with MVPA. Specifically, substituting 30 min of SB with MVPA was associated with a decrease in BMI z-score by −0.15 units (95% CI −0.21, −0.10) in children and lower BMI by −0.56 kg/m2 (95% CI −0.74, −0.39) in adults and by −0.52 kg/m2 (95% CI −0.61, −0.43) in older adults. Reallocating time away from sleep and LPA showed several significant changes but lacked a consistent pattern. While the predicted changes in obesity indicators were generally consistent across age groups, inconsistent findings were observed in adolescents, particularly for reallocations between MVPA and other behaviors. Conclusions: This investigation emphasizes the crucial role of MVPA in mitigating obesity risk across the lifespan, and the benefit of substituting SB with low-intensity movement behaviors. The distinct patterns observed in adolescents suggest a need for age-specific lifestyle interventions to effectively address obesity. Emphasizing manageable shifts, such as 10-min reallocations, could have significant public health implications, promoting sustainable lifestyle changes that accommodate individuals with diverse needs, including those with severe obesity., This study was supported by grants from the Czech Science Foundation (18-09188S and 22-02392S). ART and ICR are supported by the Ministry of Economy and Competitiveness-Carlos III Health Institute (FIS PI19/01919). BPC was supported by the Government of Andalusia (Spain), Research Talent Recruitment Program (EMERGIA 2020/00158). CM is funded by the National Health and Medical Research Council Australia, project grant (APP1080186). DL is funded by the National Health and Medical Research Council Australia (APP1120518) and the New South Wales Department of Education School Sport Unit. EVG and MAG are supported by the Spanish Ministry of Economy and Competitiveness (DEP2015-63988-R, MINECO-FEDER). JPC is supported by the Development and Innovation Programme (PAIDI P20_1181) of the Government of Andalusia and Ministry of Universities (22330) and the European Union\u2014NextGenerationEU program for the requalification of university teaching staff. KMJ and PS are supported by the University of Otago (Grant number ORG 0114\u20131015) and National Heart Foundation of New Zealand (Grant number 1618). SS is supported by the French National Research Agency (ANR-19-CE36-0004-01) and by the European Union (ERC, RHYTHM IN DEMENTIA, 101043884). The Whitehall II study has been supported by grants from the National Institute on Aging, National Institutes of Health (R01AG056477, RF1AG062553), UK Medical Research Council (R024227, S011676, K013351), the British Heart Foundation (RG/16/11/32334), and the Wellcome Trust (221854/Z/20/Z). The funding of the Seniors-ENRICA-2 study (DMG and VCS) was obtained from grants FIS 22/01111, PI23/00663, and PMP22/00002 from the Carlos III Health Institute (ISCIII), the State Secretary of R\u2009+\u2009D\u2009+\u2009I, and the Pluri-regional program Spain ERDF 2021\u20132027, the MCIN/AEI/10.13039/501100011033 and the European Union \u201CNextGenerationEU/PRTR\u201D (PLEC2022-009352 grant), and the ISCIII-CDTI and the European Union \u201CNextGenerationEU/PRTR\u201D (PMPTA22/00107 grant).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis

  • Blanco García, Francisco J
  • Quaranta, Patricia
  • Domínguez-Guerrero, Pablo
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Balboa-Barreiro, Vanesa
  • Noriega-Cobo, Diana M.
  • Galindo, Laura
  • Acasuso, Belén
  • Oreiro Villar, Natividad
  • Rojo, Ricardo
  • Lourido, Lucía
  • Ruiz-Romero, Cristina
[Abstract] Background: Reliable biomarkers predicting which patients with rheumatoid arthritis (RA) can safely undergo biologic tapering are currently lacking. This study aimed to identify circulating protein biomarkers predictive of flare during biologic disease-modifying anti-rheumatic drug tapering in RA. Methods: Baseline serum samples from patients with RA in sustained remission enrolled in the Biologic Optimisation (OPTIBIO) clinical trial were analysed using a two-stage design comprising an exploratory mass spectrometry in a discovery sample subset (n=44, 22 in the optimisation arm and 22 in the control arm), followed by ELISA validation of selected protein biomarkers and anti-cytokine autoantibody profiling in the full cohort (n=194). The primary outcome was a disease flare during follow-up. Results: During follow-up, disease flare occurred in 46.4% of patients in the optimisation arm and 30.9% in the control arm. Within the discovery subset of the optimisation arm, 87 proteins were differentially abundant between patients who flared and those who remained in remission. V-set immunoglobulin-domain-containing 4 (VSIG4) was validated as a biomarker associated with increased flare risk while anti-interferon-γ (anti-IFNγ) autoantibodies were also independently associated with flare. A combined model integrating VSIG4, anti-IFNγ and Disease Activity Score 28-joint count using C reactive protein improved discrimination compared with the clinical model alone (area under the curve (AUC) 0.760 vs 0.666) and showed higher sensitivity and greater potential clinical utility in decision curve analysis. In a secondary exploratory subgroup of patients with prolonged remission, predictive performance further improved (AUC 0.839). Conclusion: These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies. External validation is required before clinical implementation., This work was supported by the Instituto de Salud Carlos III (ISCIII) through the projects PI20/00793, PI22/01155, PMP22/00101 and PI23/00818 (to FJB and CRR) and co-funded by the European Union. Additional funding was provided by Xunta de Galicia (grants IN607D2020/10, IN607A2021/07, and IN607A2025/11). LL was supported by a Sara Borrell Fellowship (CD19/00229). VC is supported by grant RD24/00070026, funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union. RPG is supported by Programa de axudas á etapa posdoutoral from Xunta de Galicia (IN606B-2024.22). The Biomedical Research Networking Center (CIBER) is an initiative of ISCIII (CB06/01/0040). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses)

  • Hernáez, Álvaro
  • Camps-Vilaró, Anna
  • Polo-Alonso, Sara
  • Subirana, Isaac
  • Ramos, Rafel
  • Cid, Rafael de
  • Rodriguez Artalejo, Fernando
  • Elosua, Roberto
  • Chirlaque, Maria-Dolores
  • Amiano, Pilar
  • Bermúdez-López, Marcelino
  • Guevara, Marcela
  • Cinza-Sanjurjo, Sergio
  • Sánchez, María-José
  • Cabrera de León, Antonio
  • Laclaustra, Martin
  • Rojo-Martínez, Gemma
  • Guembe, María Jesús
  • Pérez-Gómez, Beatriz
  • Vega Alonso, Tomás
  • Torán-Monserrat, Pere
  • Lora-Pablos, David
  • Huerta, José María
  • Valdivielso, Jose Manuel
  • Degano, Irene R.
  • Félix-Redondo, Francisco J.
  • Gandarillas, Ana María
  • Valdés, Sergio
  • Mundet-Tudurí, Xavier
  • Sánchez, Pedro L.
  • Martín Sánchez, Vicente
  • Rigo, Fernando
  • Alonso-Sampedro, Manuela
  • Moreno Iribas, Conchi
  • Martín-Escudero, Juan Carlos
  • Delgado, Elías
  • Grau, Maria
  • Urrutia, Inés
  • Ovejero, Diana
  • Quintela, Inés
  • Martí Lluch, Ruth
  • Blay, Natalia
  • Banegas, José R.
  • Tizón-Marcos, Helena
  • Humberto Gómez, Jesús
  • Aizpurua, Amaia
  • Castro-Boqué, Eva
  • Delfrade, Josu
  • Prieto-Díaz, Miguel Ángel
  • Rodríguez-Barranco, Miguel
  • Almeida, Delia
  • Moreno-Franco, Belén
  • Oualla Bachiri, Wasima
  • Sayón-Orea, Carmen
  • Plans-Beriso, Elena
  • Lozano Alonso, Jose Eugenio
  • López-Lifante, Víctor-Miguel
  • Cancelas-Navia, Pilar
  • Cabrera-Castro, Natalia
  • Cambray, Serafí
  • Zacarías-Pons, Lluís
  • Fernández-Bergés, Daniel
  • Donoso-Navarro, Encarnacion
  • Maldonado-Araque, Cristina
  • Franch-Nadal, Josep
  • Dorado-Díaz, Pedro Ignacio
  • Villarín Castro, Alejandro
  • Frontera-Juan, Guillem
  • Gude, Francisco
  • Andueza, Naroa
  • Téllez-Plaza, María
  • Ares, Jessica
  • Cruz, Raquel
  • Ribas Aulinas, Marc
  • Barretina, Jordi
  • Guallar-Castillon, Pilar
  • Cainzos-Achirica, Miguel
  • Colorado-Yohar, Sandra
  • Llorente, Adrián
  • Díaz Tocados, Juan Miguel
  • Ardanaz, Eva
  • Micó-Pérez, Rafael Manuel
  • Fernandez-Martinez, Nicolás Francisco
  • Rodríguez-Pérez, María del Cristo
  • Cenarro, Ana
  • Calle-Pascual, Alfonso L.
  • Marrugat, Jaume
The CORDELIA Study (Collaborative Cohorts Reassembled Data to Study Mechanisms and Long-term Incidence of Chronic Diseases) combines 35 Spanish population cohorts to investigate the clinical, environmental, genetic, and omics determi-nants of cardiovascular disease in the Southern European population. It aims to conduct the largest genome-wide association study to date on cardiovascular disease in this population, improve predictions of cardiovascular incidence using genomic and clinical data, and identify subgroups that would benefit most from targeted pharmacological and lifestyle interven-tions. CORDELIA includes 196,632 individuals (ages 18–84, 54% female, 96% born in Spain, 20% with higher education, recruited from 1989 to 2020, with follow-up periods ranging from 5 to 30 years), with DNA samples available for 117,342 participants (60%). Of the participants, 24% were current smokers, 43% hypertensive, 11% diabetic, 15% medicated with lipid-lowering drugs, 44% overweight, and 27% obese. If not already available, genotyping is being performed using the Axiom™ Spain Biobank array (~ 750,000 variants, including 115,000 specific and 50,000 rare functional variants from the Spanish population). The cohort also includes incident events (coronary heart disease, stroke, heart failure, peripheral artery disease, hypertension, diabetes); date and cause of death; and harmonized data on risk factors (body mass index, waist circumference, lipid profile, blood pressure, glucose, creatinine), lifestyle (smoking, physical activity, diet, alcohol), and socioeconomic status. 99,019 participants (50%) also provide plasma samples. CORDELIA will significantly contribute to understanding the complex interplay of risk factors contributing to cardiovascular disease and advance the fields of precision medicine and public health in Southern European individuals., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease in severe obesity and concordance between Invasive (Biopsy) and noninvasive (OWLiver®) diagnoses

  • Navarro Masip, Èlia
  • Mestres Petit, Núria
  • Salinas-Roca, Blanca
  • Herrerías, Fernando
  • Vilardell, Felip
  • de la Fuente, Mari Cruz
  • Pallares, Judit
  • Santamaría Gómez, Maite
  • Zorzano-Martínez, Marta
  • Sánchez, Enric
  • Matias-Guiu, Xavier
  • López-Cano, Carolina
  • Soler, Ana Gloria
  • León-Mengíbar, Josep
  • Bueno, Marta
  • Lecube, Albert
Introduction: Nonalcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is an escalating health concern linked to obesity and type 2 diabetes. Despite liver biopsy being the gold standard, its invasiveness underscores the need for noninvasive diagnostic methods. Methods: A cross-sectional study was performed to assess MASLD using the noninvasive OWLiver® serum lipidomics test in a cohort of 117 patients with severe obesity undergoing bariatric surgery, comparing outcomes with liver biopsy. Exclusions (n = 24) included insufficient data, liver disease etiology other than MASLD, corticosteroid treatment, excessive alcohol consumption, low glomerular filtration rate, and declination to participate. Comprehensive laboratory tests, demographic assessments, and liver biopsies were performed. Serum metabolites were analyzed using OWLiver®, a serum lipidomic test that discriminates between healthy liver, steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and MASH with fibrosis ≥2 by means of three algorithms run sequentially. Results: Liver biopsy revealed a MASLD prevalence of 95.7%, with MASH present in 28.2% of cases. OWLiver® demonstrated a tendency to diagnose more severe cases. Body mass index (BMI), rather than the presence of type 2 diabetes, emerged as the sole independent factor linked to the probability of concordance. Therefore, the all-population concordance of 63.2% between OWLiver® and liver biopsy notably raised to 77.1% in patients with a BMI <40 kg/m2. These findings suggest a potential correlation between lower BMI and enhanced concordance between OWLiver® and biopsy. Conclusion: This study yields valuable insights into the concordance between liver biopsy and the noninvasive serum lipidomic test, OWLiver®, in severe obesity. OWLiver® demonstrated a tendency to amplify MASLD severity, with BMI values influencing concordance. Patients with BMI <40 kg/m2 may derive optimal benefits from this noninvasive diagnostic approach., info:eu-repo/semantics/publishedVersion
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lamb–Shaffer syndrome: 20 Spanish patients and literature review expands the view of neurodevelopmental disorders caused by SOX5 haploinsufficiency

  • Tenorio-Castaño, Jair Antonio
  • Gómez, Á.S.A.
  • Coronado, M.
  • Rodríguez-Martín, Pilar
  • Parra, A.
  • Pascual, P.
  • Cazalla, M.
  • Gallego, Natalia
  • Arias, Pedro
  • Morales, Aixa V.
  • Nevado, Julian
  • Lapunzina, Pablo
Lamb–Shaffer Syndrome (LSS; OMIM #616803; ORPHA #313892; ORPHA #313884) is an infrequent genetic disorder that affects multiple aspects of human development especially those related to the development of the nervous system. LSS is caused by variants in the SOX5 gene. At the molecular level, SOX5 gene encodes for a transcription factor containing a High Mobility Group (HMG) DNA-Binding domain with relevant functions in brain development in different vertebrate species. Clinical features of Lamb–Shaffer syndrome may include intellectual disability, delayed speech and language development, attention deficits, hyperactivity, autism spectrum disorder, visual problems and seizures. Additionally, patients with the syndrome may present distinct facial dimorphism such as a wide mouth with full lips, small chin, broad nasal bridge, and deep-set eyes. Other physical features that have been reported in some patients include short stature, scoliosis, and joint hypermobility. Here, we report the clinical and molecular characterization of a Spanish LSS cohort of new 20 patients and review all the patients published so far which amount for 111 patients. The most frequent features included developmental delay, intellectual disability, visual problems, poor speech development and facial dysmorphic features. Strikingly, pain insensitivity and hypermetropia seems to be more frequent than previously reported, based on the frequency seen in the Spanish cohort. Eighty-three variants have been reported so far, single nucleotide variants (SNV) and copy number variants represent 47% and 53%, respectively, from the total of variants reported. Similarly to previous reports, the majority of the SNVs variants of the novel patients reported herein fall in the HMG domain of the protein. However, new variants, affecting other functional domains, were also detected. In conclusion, LLS is a rare genetic disorder mostly characterized by a wide range of developmental and neurological symptoms. Early diagnosis would allow to start of care programs, clinical follow up, prospective studies and appropriate genetic counseling, to promote clinical and social improvement to have profound lifelong benefits for patients and their families. Further research is needed to better understand the underlying mechanisms of the syndrome related to SOX5 haploinsufficiency., European Regional Development Fund;Instituto de Salud Carlos III, Grant/AwardNumbers: PI20/01053, PMP22/00049,PMP21/00063, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular studies of phages-Klebsiella pneumoniae in mucoid environment: innovative use of mucolytic agents prior to the administration of lytic phages

  • Pacios, Olga
  • Blasco, Lucía
  • Ortiz-Cartagena, Concha
  • Bleriot, Inés
  • Fernández-García, Laura
  • López, María
  • Barrio-Pujante, Antonio
  • Fernández-Cuenca, Felipe
  • Aracil, Belén
  • Oteo-Iglesias, Jesús
  • Tomás, María
© 2023 Pacios, Blasco, Ortiz Cartagena, Bleriot, Fernández-García, López, Barrio-Pujante, Cuenca, Aracil, Oteo-Iglesias and Tomás. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms., Mucins are important glycoproteins that form a protective layer throughout the gastrointestinal and respiratory tracts. There is scientific evidence of increase in phage-resistance in the presence of mucin for some bacterial pathogens. Manipulation in mucin composition may ultimately influence the effectiveness of phage therapy. In this work, two clinical strains of K. pneumoniae (K3574 and K3325), were exposed to the lytic bacteriophage vB_KpnS-VAC35 in the presence and absence of mucin on a long-term co-evolution assay, in an attempt to mimic in vitro the exposure to mucins that bacteria and their phages face in vivo. Enumerations of the bacterial and phage counts at regular time intervals were conducted, and extraction of the genomic DNA of co-evolved bacteria to the phage, the mucin and both was performed. We determined the frequency of phage-resistant mutants in the presence and absence of mucin and including a mucolytic agent (N-acetyl L-cysteine, NAC), and sequenced them using Nanopore. We phenotypically demonstrated that the presence of mucin induces the emergence of bacterial resistance against lytic phages, effectively decreased in the presence of NAC. In addition, the genomic analysis revealed some of the genes relevant to the development of phage resistance in long-term co-evolution, with a special focus on the mucoid environment. Genes involved in the metabolism of carbohydrates were mutated in the presence of mucin. In conclusion, the use of mucolytic agents prior to the administration of lytic phages could be an interesting therapeutic option when addressing K. pneumoniae infections in environments where mucin is overproduced., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI19/00878 and PI22/00323 and co-funded by the European Union, and by the Study Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA (SEIMC). (SEIMC, http://www.seimc.org/). This research was also supported by CIBERINFEC (CIBER21/13/00095) and by Personalized and precision medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092). MT was financially supported by the Miguel Servet Research Programme (SERGAS and ISCIII). OP, LF-G, and ML were financially supported by the grants IN606A-2020/035, IN606B-2021/013, and IN606C-2022/002, respectively (GAIN, Xunta de Galicia). IB was financially supported by the pFIS program (ISCIII, FI20/00302)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Míes, Belén
  • Redondo, Andrés
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana
  • D’Angelo, Emanuela
  • Hardisson, David
  • Vieites, Begoña
  • Matías-Guiu, Xavier
  • Estévez-García, Purificación
  • Guerra, Eva
  • Prat, Jaime
  • Poveda, Andrés
  • López-Guerrero, José Antonio
  • Palacios Calvo, José
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (>20 TILs/core), low/intermediate CD4+ (<20 TILs/core) and high CD8+/CD4+ ratio (>35/core) were associated with favorable outcomes. Tumor cell PD-L1 expression (TPS ≥ 1) was present in only 8% of tumors. In total, 11 (16%) and 6 (9%) out of 69 HGSOC tested carried pathogenic or likely pathogenic BRCA1 or BRCA2 mutations, respectively. Median TMB of 40 tumors analyzed was 5.04 mutations/Mb and only 6 tumors had 10 or more mutations/Mb. BRCA status and TMB were not associated with TILs or prognosis. When compared with studies on advanced HGSOC, our results suggested that prognostic variables differed according to stage and that more studies focused on early stages of HGSOC are needed to better stratify these tumors., This work was supported by Instituto de Salud Carlos III (ISCIII) (grants PI19/01331, PI22/01892 and PMP22/00054); CIBERONC (grant CB16/12/00316); European Development Regional Fund ‘A way to achieve Europe’ (FEDER), Spanish Group of Research in Ovarian Cancer (GEICO group); and by the Spanish Association Against Cancer Scientific Foundation (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation

  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
  • Vargas Padilla, María Victoria
  • Lobo Selma, Laura
  • Chacón-Barrado, Antonio
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings., E.d.Á. laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to E.d.Á., Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to E.d.Á., ECAEC222952DEAL, Fundación Científica AECC to E.d.Á, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to F.O. Fundación Domingo Martínez to F.O. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to D.D.-B. Fundación Getthi ONC18PE01/2022 to E.d.Á., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pursuing precision in medicine and nutrition: the rise of electrochemical biosensing at the molecular level

  • Campuzano, Susana
  • Barderas, Rodrigo
  • Moreno-Casbas, Maria Teresa
  • Almeida, Ángeles
  • Pingarrón, José Manuel
In the era that we seek personalization in material things, it is becoming increasingly clear that the individualized management of medicine and nutrition plays a key role in life expectancy and quality of life, allowing participation to some extent in our welfare and the use of societal resources in a rationale and equitable way. The implementation of precision medicine and nutrition are highly complex challenges which depend on the development of new technologies able to meet important requirements in terms of cost, simplicity, and versatility, and to determine both individually and simultaneously, almost in real time and with the required sensitivity and reliability, molecular markers of different omics levels in biofluids extracted, secreted (either naturally or stimulated), or circulating in the body. Relying on representative and pioneering examples, this review article critically discusses recent advances driving the position of electrochemical bioplatforms as one of the winning horses for the implementation of suitable tools for advanced diagnostics, therapy, and precision nutrition. In addition to a critical overview of the state of the art, including groundbreaking applications and challenges ahead, the article concludes with a personal vision of the imminent roadmap., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The financial support of PID2019-103899RB-I00 (Spanish Ministerio de Ciencia e Innovación), and PMP22/00084, PI17CIII/00045, PI20CIII/00019 and PI22/00727 (AES-ISCIII) co-founded with FEDER funds Research Projects and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) are gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study

  • Boluda, Blanca
  • Rodriguez-Veiga, Rebeca
  • Sargas, Claudia
  • Ayala, Rosa
  • Larráyoz, María José
  • Chillón, María Carmen
  • Soria-Saldise, Elena
  • Bilbao, Cristina
  • Prados de la Torre, Esther
  • Navarro, Irene
  • Martínez-Cuadrón, David
  • Gil, Cristina
  • Bernal, Teresa
  • Bergua, Juan
  • Algarra, Lorenzo
  • Tormo, Mar
  • Martínez-Sánchez, Pilar
  • Carrillo-Cruz, Estrella
  • Serrano, Josefina
  • Alonso-Domínguez, Juan Manuel
  • García, Raimundo.
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Sayas, María-José
  • Lavilla-Rubira, Esperanza
  • García-Pérez, María José
  • Morán, Julia
  • Pérez-Santaolalla, Esther
  • Alonso-Vence, Natalia
  • Oliva, Ana
  • López, Juan Antonio
  • Barrios, Manuel
  • García-Fortes, María
  • Olave, María Teresa
  • Labrador, Jorge
  • Martínez-López, Joaquín
  • Calasanz, Mª Jose
  • García-Sanz, Ramón
  • Pérez-Simón, José A.
  • Gómez-Casares, María T
  • Sánchez-García, Joaquín
  • Mendizabal, Yolanda
  • Barragán, Eva
  • Montesinos, Pau
(This article belongs to the Special Issue New Approaches in Leukemia)., The authors would like to thank all the PETHEMA institutions and clinicians, PETHEMA data managers for data collection and management, and the central laboratory staff for sample management. A complete list of the institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia appears in the Supplementary Materials “Appendix”., [Simple Summary] This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR (analytical sensitivity 3%) in a nationwide network of seven reference laboratories. Between 2019 and 2021, 1685 adult acute myeloid leukemia (AML) patients with at least one centralized sample (NGS or PCR) at primary diagnosis or relapse/refractory episode were included, and 1288 paired NGS/PCR samples were analyzed. Considering PCR the gold-standard, for NPM1 NGS sensitivity was 98.5% and specificity 98.9%, for FLT3-ITD 73.8% and 99.6%, for FLT3-TKD 84.5% and 99.3%, for IDH1 98.7% and 98.7%, and for IDH2 99.1% and 97.7%, respectively. Overall, median days from sample reception until report were 7 for PCR and 28 for NGS. This study shows high concordance between NPM1 and IDH results using PCR and NGS. However, sensible important discrepancies are observed for FLT3 mutations., [Abstract] Background/Objectives: This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR (analytical sensitivity 3%) in a nationwide network of seven reference laboratories. Methods: Between 2019 and 2021, 1685 adult AML patients with at least one centralized sample (NGS or PCR) at primary diagnosis or relapse/refractory episode were included. Results: During this period, 1288 paired NGS/PCR samples (1094 at diagnosis, 103 at relapse and 88 at refractoriness) were analyzed. Considering PCR the gold-standard, for NPM1 NGS sensitivity was 98.5% and specificity 98.9%, for FLT3-ITD 73.8% and 99.6%, for FLT3-TKD 84.5% and 99.3%, for IDH1 98.7% and 98.7%, and for IDH2 99.1% and 97.7%, respectively. Overall concordance rate of positive results between NGS (and PCR was 95% (262/276) for NPM1, 72% (149/206) for FLT3-ITD, 74% (49/66) for FLT3-TKD, 87% (77/89) for IDH1 and 84% (107/127) for IDH2. Overall, median days from sample reception until report were 7 for PCR and 28 for NGS. Conclusions: This study shows high concordance between NPM1 and IDH results using PCR and NGS. However, sensible important discrepancies are observed for FLT3 mutations. In our context, rapid screening for these druggable mutations should be performed by conventional PCR., This study was supported in part by Novartis and PMP22/00069, PI18/01340, PI18/01946 and PI21/01705 Instituto de Salud Carlos III grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

  • Hernando-Amado, Sara
  • Gomis-Font, María A
  • Valverde, José R.
  • Oliver, Antonio
  • Martínez Menéndez, José Luis
Ceftazidime-avibactam is a β-lactam/β-lactamase inhibitor combination restricted for the treatment of multidrug-resistant infections of Pseudomonas aeruginosa non-susceptible to ceftazidime and resistant to carbapenems. Crucially, it has not been studied if its use could allow the design or application of new or stablished evolution-based strategies that exploit the increased susceptibility that emerges when resistance is acquired (collateral sensitivity, CS). Works in the field have focused on the study of CS in model strains, but to be exploited it must robustly emerge in pre-existing resistant mutants that can coexist in a patient. This is the first analysis of CS robustness on this last-resort drug. We evolved 15 clinical isolates on ceftazidime-avibactam and in absence of inhibitor, and here we show that we found no robust -exploitable- pattern of CS. This, together with the selection of cross-resistance and the impossibility of using previously described CS-based strategies, supports that avibactam should be restricted for the treatment of particular genotypes., This work was supported by MICIU/AEI/10.13039/501100011033 and FEDER (UE) -grant PID2023-149913OA-I00- to S.H.A. and by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU -grants PI21/00017 and Personalized and precision medicine grant MePRAM Project PMP22/00092- to A.O. The MICIU/AEI/ 10.13039/501100011033 is also acknowledged for supporting the National Center for Biotechnology through the “Severo Ochoa” grant CEX2023-001386-S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

  • García-González, Pablo
  • Díaz Belloso, Rafael
  • Munoz-Delgado, Laura
  • Buiza Rueda, Dolores
  • Gómez-Garre, Pilar
  • Pérez-Tur, Jordi
  • Real, Luis M.
  • Bullido, María Jesús
  • Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R  +  D  +  I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

  • Olmedo-Pelayo, Joaquín
  • Granado-Calle, Esperanza
  • Delgado-Bellido, Daniel
  • Lobo Selma, Laura
  • Jordán-Pérez, Carmen
  • Monteiro-Amaral, Ana T.
  • Ehlers, Anna C.
  • Ohmura, Shunya
  • García-Domínguez, Daniel
  • Mackintosh, Carlos
  • Carcaboso, Ángel M.
  • Alonso García de la Rosa, Francisco Javier
  • Machado, Isidro
  • Llombart-Bosch, A.
  • Scotlandi, Katia
  • Grünewald, Thomas G. P.
  • Gómez-Herreros, Fernando
  • Álava, Enrique de
Drug resistance is an ill-defined cause of dismal outcomes in cancer. Ewing sarcoma (EwS), a pediatric cancer characterized by high therapy failure rates, is driven by a single oncogenic event generating EWSR1::ETS gene fusions (primarily EWSR1::FLI1) in a silent genomic background. This provides a straightforward model to study the impact of gene fusions on drug responses. Here, we describe a novel mechanism of sensitivity to DNA topoisomerase 1 poisons in EwS. We discovered that EWS::FLI1 prevents the resolution of R-loops induced by these drugs via sequestering DHX9 helicase, ultimately resulting in R-loop accumulation, replication stress, and genome instability. In turn, excessive DHX9 or reduced EWS::FLI1 levels render EwS cells resistant to the active metabolite of irinotecan (SN-38) independent of proliferation and global transcription rates. This resistance helps explain how elevated DHX9 levels predict worse clinical outcomes. Overall, our research demonstrates the impact of a dominant mutation on cancer drug sensitivity, highlighting its significant clinical implications., JO-P is supported by Ph.D. grant Plan Propio from the University of Seville. DD-B is supported by Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_21_00865). DJG-D was supported by the VII Plan Propio de Investigación y Transferencia de la Universidad de Sevilla [Contrato de Acceso (II.4)/VII PPIT-US]. The laboratory of JA is supported by Instituto de Salud Carlos III (grant numbers PI20CIII/00020, DTS22CIII/00003, PMP21-00073); Asociación Pablo Ugarte (TRPV205/18, DGDO195722); Asociación Candela Riera, Asociación Todos Somos Iván & Fundación Sonrisa de Alex (TVP333-19, TVP-1324/15). The laboratory of TGPG is supported by grants from the Matthias-Lackas Foundation, the Dr. Leopold und Carmen Ellinger Foundation, the Deutsche Forschungsgemeinschaft (DFG 458891500), the German Cancer Aid (DKH-7011411, DKH-70114278), the Boehringer-Ingelheim foundation, the Dr. Rolf M. Schwiete foundation, the SMARCB1 association, the Ministry of Education and Research (BMBF; SMART-CARE and HEROES-AYA) and the Barbara and Wilfried Mohr foundation. A.C.E. was supported by a scholarship from the German Cancer Aid. The laboratory of FG-H is supported by grants funded by MCIN/AEI/10.13039/501100011033/FEDER, UE (R + D + i PID2019-105212GB-I00 and PID2022-137143NB-I00) and the Andalusian Regional Government: Fondo Europeo de Desarrollo Regional (FEDER) y Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (P20_00561) to FG-H. The laboratory of EdA is supported by grants from ISCIII-FEDER (PI20/00003, PI23/1460 and PMP22/00054), Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018, PI-0061-2020), Fundación Científica AECC (ECAEC222952DEAL), Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC Instituto de Salud Carlos III, CB16/12/00361., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications

  • Viana-Errasti, Julen
  • Marín, Raúl
  • García-Mulero, Sandra
  • Pons, Tirso
  • Terradas, Mariona
  • Capellá, Gabriel
  • Moreno, Victor
  • Mur, Pilar
  • Valle, Laura
Supplementary Material https://www.sciencedirect.com/science/article/pii/S0893395225001401?via%3Dihub#cebib0010:~:text=This,publication, Polymerases ε and δ maintain genome integrity through exonuclease proofreading. Germline and somatic pathogenic variants (PVs) in the exonuclease domain (ED) of POLE and POLD1 impair proofreading, causing hypermutated tumors. Despite shared mutational features that make these tumors highly immunogenic, molecular and clinical distinctions between POLE and POLD1 mutations and between somatic and germline variants remain incompletely understood. We compared the molecular and clinical characteristics of POLE and POLD1 ED PVs (n = 31), assessing their location, pathogenicity, clinical phenotypes, mismatch repair (MMR) status, tumor mutational burden, and signatures. We analyzed 360 proofreading-deficient tumors (source: The Cancer Genome Atlas [TCGA] and Catalogue Of Somatic Mutations In Cancer [COSMIC]) and 70 families (249 individuals) with polymerase proofreading-associated polyposis. All germline and somatic PVs had high AlphaMissense scores (0.87-1) and clustered within or near Exo motifs. Recurrent, nonfounder germline PVs, POLE L424V and POLD1 S478N, showed low/modest REVEL scores. Somatic variants occurred mainly in endometrial cancers (75% of proofreading-deficient TCGA cancers), whereas colorectal cancer predominated in polymerase proofreading-associated polyposis (56% of carriers). Cancer risks and tumor spectra differed between POLE and POLD1 PV carriers. Aggressive hereditary phenotypes were linked to either specific POLE PVs (eg, S297F, V411L, P436R, M444K, A456P, and S461T) or the co-occurrence of germline ED PVs with germline MMR gene PVs. Distinct hypermutator profiles were confirmed for polymerase ε and polymerase δ proofreading deficiencies via unique mutational signatures (Polymerase ε: SBS10a/b, SBS28; Polymerase δ: SBS10c/d). Tumors with combined proofreading and MMR deficiencies had significantly higher tumor mutational burden and a shift in the associated mutational spectra. Unlike POLE, POLD1 ED PVs exhibited haplosufficiency, typically requiring a somatic second hit (eg, loss of heterozygosity) or MMR deficiency to drive hypermutation. In conclusion, differences between POLE and POLD1 and between somatic and germline mutations influence clinical presentation, mutagenic potential, and reliance on cooperating defects in tumorigenesis. These insights advance the understanding of proofreading-deficient cancers, with implications for diagnostics, genetic counseling, and precision oncology., This study was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), cofunded by FEDER funds a way to build Europe (PID2024-162582OB-I00; PID2020-112595RB-I00, AEI/10.13039/501100011033 and “Contrato predoctoral para la formación de doctores” [J.V.-E.]); Instituto de Salud Carlos III [CIBERONC CB16/12/00234; PMP22/00064, also funded by NextGenerationEU (MRR)/PRTR]; Government of Catalonia [AGAUR 2021SGR01112; CERCA Program for institutional support (IDIBELL)]. None of the study sponsors had any involvement in the study design, collection, analysis and interpretation of data, writing of the report and decision to submit the article for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comprehensive profiling of Aβ40 and Aβ42 fibril-interacting proteins reveals PRKCG as a drug-targetable regulator of amyloidogenesis in Alzheimer's disease

  • Montero-Calle, Ana
  • Coronel, Raquel
  • Manosalva, Juliana
  • Megías, Diego
  • Ríos, Vivian de los
  • Rábano, Alberto
  • Peláez-García, Alberto
  • Martínez-Useros, Javier
  • Fernández-Aceñero, María Jesús
  • Liste, Isabel
  • Barderas, Rodrigo
Proteins interacting with amyloid beta (Aβ) fibrils could be key to plaque formation in Alzheimer's disease (AD) and represent potential biomarkers and therapeutic targets. Previous proteomic studies using microdissected plaques might have captured non-specific components rather than true Aβ interactors., We gratefully acknowledge the invaluable technical support provided by the Unidad de Microscopía Electrónica of the Instituto de Salud Carlos III. We acknowledge the financial support of the PMP22/00084 grant of the 2022 personalized medicine call from the Instituto de Salud Carlos III (ISCIII), the PI17CIII/00045 grant from the AES-ISCIII program, and grant PID2022-140307OB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to R.B.; R.C. and I.L. acknowledge grant PID2021-126715OB-I00 financed by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” and PI22CIII/00055 funded by the AES-ISCIII program from ISCIII. A.M.-C. was supported by a predoctoral contract of the Fundación Tatiana Pérez de Guzmán El Bueno, followed by a FPU predoctoral supported by the Spanish Ministerio de Educación, Cultura y Deporte and a postdoctoral grant associated with the PMP22/00084 project of ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An international Delphi survey on priorities in antimicrobial resistant infections therapeutic research: A preliminary study of MePRAM project

  • Cogliati Dezza, Francesco
  • Olivares Navarro, Paula
  • Caponcello, Maria Giulia
  • Salazar Moscoso, Marcela
  • Cosano Pérez, Patricia
  • Retamar Gentil, Pilar
  • Alonso González, Isabela
  • Oteo-Iglesias, Jesús
  • Torre-Cisneros, Julián
  • Horcajada, Juan Pablo
  • Rodríguez-Baño, Jesús
[Background] Due to the public health, economics and societal impacts of antibiotic-resistant bacteria, it is urgent to establish the research priorities for clinical trials development in the antimicrobial resistance (AMR) field. The objective of this study was to derive a consensus document on the prioritization of AMR topics for the development of randomized trials., [Methods] We performed a survey using the Delphi methodology to establish a consensus among international experts on AMR priority. The questionnaire consisted of 114 items divided in four domains (1.Microorganisms and antimicrobial resistance, 2.Clinical syndromes, 3.Specific populations, 4.Anti-infective agents). The survey was administered to 60 experts using REDCap platform between January and September 2024. Consensus was defined as a simple or cumulative agreement ≥ 70 %. After each round, the results were discussed in Steering Committee meetings and feedback was provided to the experts. A final meeting was held to finalize the priority lists., [Results] Consensus was reached in 101 items with high priority in 47 items. We elaborated four ranked priority list in the microorganisms and antimicrobial resistance domain divided in four different sections, one priority list addressing the clinical syndromes domain, one priority list addressing the specific populations domain, two priority list on anti-infective agents divided in old and new drugs. Finally, we included a 5th domain, consisting of mixed of previous sections. A priority list for each section was proposed., [Conclusions] We have established priority lists on AMR-related aspects. The priority list included pathogens, syndromes, populations and drugs and should be useful to drive future clinical research in AMR., This work was supported by Personalized and precision medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB21/13/00012, CB21/13/00002, CB21/13/00049, CB21/13/00095)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Phage Therapy for Bone and Joint Infections: Towards Clinical Translation

  • Ortiz-Cartagena, Concha
  • Blasco, Lucía
  • Bleriot, Inés
  • Esteban, Jaime
  • Toro, María Dolores del
  • Pozo, José Luis del
  • Tomás, María
This article belongs to the Special Issue Bone and Joint Infections: The Challenges of Prevention, Diagnosis and Treatment and Opportunities for Future Research., Osteoarticular infections (OAIs), including osteomyelitis, septic arthritis, prosthetic joint infections, and facture-related infections, remain a major challenge due to biofilm formation and the prevalence of multidrug-resistant (MDR) pathogens. Although OAIs are predominantly caused by Staphylococcus aureus and coagulase-negative staphylococci, the increasing incidence of MDR Gram-negative infections adds further complexity to their management. Standard approaches, combining surgery and prolonged antibiotic therapy, frequently result in recurrence and poor outcomes. Bacteriophage (phage) therapy has emerged as a promising adjunct or alternative approach, offering high host specificity, replication at the infection site, and activity against biofilm-embedded bacteria. This review highlights recent advances in phage therapy for OAIs, focusing on administration routes (intravenous, intra-articular, topical, and oral) and on novel pharmaceutical delivery systems such as hydrogels, bone cements, microparticles, nanoparticles, and implant coatings. Preclinical and early clinical studies have analyzed phage stability, controlled release, and the synergistic effects of combined phage/antibiotic therapy. However, challenges remain regarding standardization, immunogenicity, and regulatory approval. Nonetheless, phage therapy shows promise for clinical translation as an adjunct or alternative to conventional treatments for OAIs. Well-designed clinical trials are urgently needed to confirm the efficacy of phage therapy, optimize delivery strategies, and integrate the treatments in routine practice. Despite encouraging outcomes for a successful clinical implementation, regulation and standardization of GMP production are required., This study was funded by grant PI22/00323 awarded to M. Tomás and PI awarded to Rafael Cantón PI19/01043 within the State Plan for R + D + I 2013–2016 (National Plan for Scientific Research, Technological Development and Innovation 2008–2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European Regional Development Fund “A Way of Making Europe” and Instituto de Salud Carlos III FEDER, CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III FEDER, and by a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092 and COOPERA Project, COOP24CIII/00009), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, funded by NextGeneration European Union funds that support the actions of the Resilience and Recovery Facility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of Sleep-disordered Breathing Management in Primary Care on Systemic Hypertension Control: Protocol for the METASLEEP Implementation Trial, Impacto del manejo de los trastornos respiratorios del sueño en atención primaria en el control de la hipertensión sistémica: protocolo para el ensayo de implementación METASLEEP

  • Pinilla, Lucía
  • Benítez, Iván
  • Moncusí-Moix, Anna
  • Torres, Gerard
  • Casanovas-Salvatella, Olga
  • Juez-García, Ivan
  • Gracia-Lavedán, Esther
  • Alonso-Fernández, Alberto
  • Caballero-Eraso, Candela
  • Cano-Pumarega, Irene
  • Boira, Ignacio
  • Egea, Carlos
  • González, Mónica
  • Mediano, Olga
  • Roncero, Alejandra
  • Roche-Campo, Ferran
  • Sánchez-Quiroga, María Ángeles
  • Chai-Coetzer, Ching Li
  • Sánchez de la Torre, Manuel
  • Barbé, Ferran
  • Batlle, Jordi de
  • Spanish Sleep Network
List of the researchers participating in the Spanish Sleep Network Laura Pozuelo, Cristiano Van Zeller, Sara Gonzalez, Begoña Brusint, Irene Moratinos, Lourdes Botanes, Irene Duque, Cristina Santos, Eduardo Jaramillo, Silvia López, Yolanda de Don Pedro, Bárbara Luna, Sonia Camaño, Ignacio Arribas, Reyes Nicolás, Esther Solano, Leticia Álvarez, Dolores Retuerta, Laura Silgado, Esther Viejo, Sofía Romero, Pilar Resano, María Castillo, José Luis Izquierdo, Gabriel Arriba, Carina Aguilar Martín, Nerea Bueno Hernández, Alessandra Queiroga Gonçalves, Esther Sauras-Colón, Jael Lorca-Cabrera, Marylène Lejeune, Zojaina Hernández Rojas, Mercè Ribes Pedret, Elisabet Martí Solé, Daniela Domenica Montalvo Barrera, Juan Manuel Carrera Ortíz, Sonia Baset Martínez, Rosa Caballol Angelats, Manuel Vicente Maestro Ibáñez, Núria Manchó Casadesús, Inmaculada Salvador-Adell, Mireia Serra-Fortuny, Luis Adolfo Urrelo Cerrón, Yessenia Flores Martínez, Eusebi Chiner, Violeta Esteban, Javier Puentes, Juan Fernando Masa, Elisabet Uribe, Vanessa Iglesias, Rafaela Vaca, Olga Mínguez, Dolores Martínez, Maria Aguilà, Lydia Pascual, María Isabel Asensio, Esther de Benito, Carlos Carrera, María José García, María Teresa López, Ana Belén Cascajo, Beatriz Pascual, María Sara Narváez, Laura Cànaves, Nuria Gayà, Mónica de la Peña, Paloma Giménez, Susana García, Maria Concepción Piñas, Jorge Julián Monroy, Lucía Gorreto, Cecilia Carina Amato, Lorenzo González, Miguel Román, Marina Mainzer, María Elena Terrón, Teresa Díaz, Juan José Ruiz, Marta Cabello, Selene Cuevas, Susana Pérez, Laura García, Olga Cantalejo, María Belén Pedraja, Belén Ricalde, Mikel Azpiazu, Sara Pueyo, Almudena Fernández, Mercedes Hernández, Leire Luengo, Jorge Ullate, Maria Viviana Muñoz, Jesus Iturralde, Margarita Pinel, Anais Cruz, Saioa Escamilla, Carlos Ruiz-Martinez, Jose Alfonso Jiménez, Fernando Gallo, Rubén Esteban, Antonio Puente, Laura Pérez-Bozalongo, Paula Vicente, Jorge Lázaro, Marta Cristeto., [EN] [Introduction] Hypertension is the leading cause of cardiovascular disease, with nocturnal blood pressure (BP) abnormalities (nocturnal hypertension and non-dipping BP) linked to heightened risk. Obstructive sleep apnea (OSA), a modifiable contributor to impaired nighttime BP regulation, commonly co-occurs with hypertension. Primary care (PC) represents a strategic setting for their integrated management. The METASLEEP study aims to develop, implement, and evaluate a novel PC-based hypertension care model incorporating OSA diagnosis, treatment, and home monitoring to improve BP control., [EN] [Objectives] To describe the rationale, design, methodology, and baseline participant characteristics of the 2024 initiation phase of the METASLEEP trial., [EN] [Material and methods] Prospective, longitudinal, real-world implementation study conducted across 10 Spanish regions (ClinicalTrials.gov NCT05986487). Adults with hypertension and no prior OSA diagnosis undergo 24-h ambulatory BP monitoring (ABPM) in PC (target n = 1523). Participants with nocturnal hypertension and/or non-dippers receive PC-led OSA diagnostic testing, treatment, and home monitoring via an under-mattress sensor. Follow-ups at 6 and 12 months evaluate changes in nighttime BP (primary) and other clinical outcomes., [EN] [Results] By end of 2024, 553 patients completed baseline ABPM. Of these, 288 (52.1%) showed nocturnal BP abnormalities: 248 (44.8%) had nocturnal hypertension and 211(38.4%) were non-dippers. Participants were middle-aged, overweight, and frequently had comorbid dyslipidemia, obesity, and diabetes. OSA prevalence was 22.6% mild, 34.1% moderate, and 35.3% severe. CPAP treatment was initiated in 79.4% of moderate-to-severe cases., [EN] [Conclusions] METASLEEP introduces a novel PC-based model integrating OSA diagnosis and management within hypertension care. Early data reveal notably high prevalence of undiagnosed OSA in hypertensive patients., [ES] [Introducción] La hipertensión es la principal causa de enfermedad cardiovascular, y las anomalías nocturnas de la presión arterial (PA) (hipertensión nocturna y PA non-dipping) se asocian a un mayor riesgo. La apnea obstructiva del sueño (AOS), un factor modificable que contribuye a la alteración de la regulación nocturna de la PA, suele coexistir con la hipertensión. La atención primaria (AP) representa un entorno estratégico para su manejo integrado. El estudio METASLEEP tiene como objetivo desarrollar, implementar y evaluar un nuevo modelo de atención a la hipertensión basado en AP que incorpore el diagnóstico, el tratamiento y la monitorización domiciliaria de la AOS para mejorar el control de la PA., [ES] [Objetivos] Describir la justificación, el diseño, la metodología y las características basales de los participantes de la fase de inicio de 2024 del ensayo METASLEEP., [ES] [Material y métodos] Estudio prospectivo y longitudinal de implementación en la práctica clínica real, realizado en 10 comunidades autónomas españolas (ClinicalTrials.gov NCT05986487). Adultos con hipertensión y sin diagnóstico previo de AOS se someten a monitorización ambulatoria de la PA (MAPA) de 24 horas en AP (n objetivo = 1523). Los participantes con hipertensión nocturna y/o non-dippers reciben pruebas diagnósticas de AOS dirigidas por AP, tratamiento y monitorización domiciliaria a través de un sensor debajo del colchón. Los seguimientos a los 6 y 12 meses evalúan los cambios en la PA nocturna (resultado principal) y otros resultados clínicos., [ES] [Resultados] A finales de 2024, 553 pacientes completaron la MAPA basal. De estos, 288 (52,1%) mostraron anomalías de la PA nocturna: 248 (44,8%) tenían hipertensión nocturna y 211 (38,4%) eran non-dippers. Los participantes eran de mediana edad, con sobrepeso y con frecuencia presentaban dislipidemia, obesidad y diabetes comórbidas. La prevalencia de AOS fue del 22,6% leve, del 34,1% moderada y del 35,3% grave. El tratamiento con CPAP se inició en el 79,4% de los casos moderados a graves., [ES] [Conclusiones] METASLEEP introduce un novedoso modelo basado en AP que integra el diagnóstico y el tratamiento de la AOS en la atención de la hipertensión. Los primeros datos revelan una prevalencia notablemente alta de AOS no diagnosticada en pacientes hipertensos., Project PMP22/00030 funded by Instituto de Salud Carlos III (ISCIII) and the European Union NextGenerationEU, which funds the Recovery and Resilience Facility (RRF); Societat Catalana de Pneumologia (beca ESTEVE TEIJIN “TERÀPIES RESPIRATÒRIES DOMICILIÀRIES” 2024); Sociedad Española de Neumología y Cirugía Torácica (convocatoria beca SEPAR 2023: 1405/2023); The study funders have no role in the study design; collection, management, analysis, and interpretation of data; writing of reports; or decision to submit reports for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

  • Coucelo, Margarida
  • Sargas, Claudia
  • Ayala, Rosa
  • Larráyoz, María José
  • Chillón, María Carmen
  • Soria, Elena
  • Bilbao, Cristina
  • Prados de la Torre, Esther
  • Amorim, Maria Luis
  • Mirales, Alberto
  • Cionfrini, Antonia
  • Simões, Ana T.
  • Oliveira, Ana C.
  • Rodríguez-Veiga, Rebeca
  • Lloret-Madrid, Pilar
  • Mendizábal, Yolanda
  • Botella, Carmen
  • Bernal, Teresa
  • Bergua, Juan
  • Algarra, Lorenzo
  • Tormo, Mar
  • Sarmento-Ribeiro, Ana Bela
  • Trigo, Fernanda
  • Cortesão, Emilia
  • Martínez-Sánchez, Pilar
  • Serrano, Josefina
  • Alonso-Domínguez, Juan Manuel
  • García, Raimundo
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Sayas, María-José
  • Abuín, Aitor
  • Martínez-López, Joaquín
  • Calasanz, María José
  • García-Sanz, Ramón
  • Gutiérrez, Norma
  • Pérez-Simón, José A.
  • Gómez-Casares, M. Teresa
  • Sánchez-García, Joaquín
  • Montesinos, Pau
  • Barragán, Eva
  • PETHEMA Group
The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of CBFB::MYH11, RUNX1::RUNX1T1 and NPM1 and one round to determine the mutational status of NPM1, FLT3 (ITD and TKD2) IDH1 and IDH2. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. FLT3-ITD and NPM1 mutation detection had 100 % concordant results. One false negative was reported for IDH2- R140 mutation and 4 false positives were detected: 2 FLT3-TKD2 and 2 IDH1-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of FLT3-TKD2 and IDH1 mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making., This study was partially funded by the Instituto de Salud Carlos III, Spain: PMP22/00069, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)

  • Gago-Veiga, Ana Beatriz
  • Lopez-Rodriguez, Ana Belen
  • Sanchez Jimenez, Marina
  • Iglesias Rubio, Alvaro
  • Montes, Nuria
  • Camiña Muñiz, Javier
  • Dominguez Gallego, Marta
  • Calle De Miguel, Carlos
  • Latorre, Germán
  • Rodriguez-Vico, Jaime
  • Jaimes, Alex
  • Gomez Garcia, Andrea
  • Urtiaga, Sarai
  • Gonzalez Salaices, Marta
  • Dileone, Michele
  • Gonzalez-García, Nuria
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Santos Lasaosa, Sonia
  • Díaz-De-Terán, Javier
  • Portocarrero-Sánchez, Leonardo
  • Casas-Limón, Javier
  • Fernández-Lázaro, Iris
Background: Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for both acute and preventive treatment of episodic migraine. Real-world data on its preventive use remain limited, particularly in patients with multiple prior preventive failures. This study evaluated the effectiveness and tolerability of rimegepant in routine clinical practice, focusing on a highly treatment-resistant population. Methods: We conducted a prospective, multicenter real-world cohort study within the GEMA (GEpants in MigrAine) Project across nine tertiary Headache Units in Spain. Adults initiating rimegepant for migraine prevention were consecutively enrolled and followed for up to 6 months. The primary endpoint was the 3-month change in monthly headache days (MHD). Secondary endpoints included the change in monthly migraine days (MMD), response rates, predictors of response, and tolerability. Baseline characteristics, prior preventive failures, medication overuse, adverse events, and patient-reported outcomes (Headache Impact Test-6 (HIT-6), HADS, and Insomnia Severity Index) were recorded. Results: In total, 150 patients completed 3-month follow-up and 64 reached 6 months. The cohort was predominantly female (85.3%), with 70.7% episodic migraine, a median age of 48 years (interquartile range (IQR) = 39–57), and a median of 6 prior preventive failures (IQR = 4–8), reflecting high treatment resistance. At 3 months, median MHD decreased from 12 to 7.5 and MMD from 10 to 6 (p < 0.05), with significant improvement in HIT-6. Overall, 36% and 43% achieved ≥ 50% reduction in MHD and MMD, respectively (≥ 75%: 15% and 20%). Among patients with 6-month data, further reductions were observed (MHD, 6 days; MMD, 5 days), with ≥ 50% response rates increasing to 48% and 58%. Clinical responders showed greater improvements in anxiety and depressive symptoms. Medication overuse, chronic migraine, and prior exposure to anti-CGRP monoclonal antibodies and onabotulinumtoxinA were independent predictors of poorer outcomes, with response declining with increasing prior anti-CGRP exposure, although a relevant proportion still achieved meaningful benefit. Rimegepant was well tolerated, with predominantly mild adverse events (nausea 13%, constipation 8%) and low discontinuation (7% at 3 months), and with nausea being the most frequent cause. Conclusions: Rimegepant showed meaningful preventive effectiveness and good tolerability in routine clinical practice, including in highly treatment-resistant patients with prior anti-CGRP monoclonal antibody exposure. The response was influenced by baseline disease burden and prior treatment exposure. These findings suggest that earlier use of rimegepant in the treatment course may be associated with greater clinical benefit.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses)

  • Hernáez, Álvaro
  • Camps-Vilaró, Anna
  • Polo-Alonso, Sara
  • Subirana, Isaac
  • Ramos, Rafel
  • Cid, Rafael de
  • Rodriguez Artalejo, Fernando
  • Elosua, Roberto
  • Chirlaque, Maria-Dolores
  • Amiano, Pilar
  • Bermúdez-López, Marcelino
  • Guevara, Marcela
  • Cinza-Sanjurjo, Sergio
  • Sánchez, María-José
  • Cabrera de León, Antonio
  • Laclaustra, Martin
  • Rojo-Martínez, Gemma
  • Guembe, María Jesús
  • Pérez-Gómez, Beatriz
  • Vega Alonso, Tomás
  • Torán-Monserrat, Pere
  • Lora-Pablos, David
  • Huerta, José María
  • Valdivielso, Jose Manuel
  • Degano, Irene R.
  • Félix-Redondo, Francisco J.
  • Gandarillas, Ana María
  • Valdés, Sergio
  • Mundet-Tudurí, Xavier
  • Sánchez, Pedro L.
  • Martín Sánchez, Vicente
  • Rigo, Fernando
  • Alonso-Sampedro, Manuela
  • Moreno Iribas, Conchi
  • Martín-Escudero, Juan Carlos
  • Delgado, Elías
  • Grau, Maria
  • Urrutia, Inés
  • Ovejero, Diana
  • Quintela, Inés
  • Martí Lluch, Ruth
  • Blay, Natalia
  • Banegas, José R.
  • Tizón-Marcos, Helena
  • Humberto Gómez, Jesús
  • Aizpurua, Amaia
  • Castro-Boqué, Eva
  • Delfrade, Josu
  • Prieto-Díaz, Miguel Ángel
  • Rodríguez-Barranco, Miguel
  • Almeida, Delia
  • Moreno-Franco, Belén
  • Oualla Bachiri, Wasima
  • Sayón-Orea, Carmen
  • Plans-Beriso, Elena
  • Lozano Alonso, Jose Eugenio
  • López-Lifante, Víctor-Miguel
  • Cancelas-Navia, Pilar
  • Cabrera-Castro, Natalia
  • Cambray, Serafí
  • Zacarías-Pons, Lluís
  • Fernández-Bergés, Daniel
  • Donoso-Navarro, Encarnacion
  • Maldonado-Araque, Cristina
  • Franch-Nadal, Josep
  • Dorado-Díaz, Pedro Ignacio
  • Villarín Castro, Alejandro
  • Frontera-Juan, Guillem
  • Gude, Francisco
  • Andueza, Naroa
  • Téllez-Plaza, María
  • Ares, Jessica
  • Cruz, Raquel
  • Ribas Aulinas, Marc
  • Barretina, Jordi
  • Guallar-Castillon, Pilar
  • Cainzos-Achirica, Miguel
  • Colorado-Yohar, Sandra
  • Llorente, Adrián
  • Díaz Tocados, Juan Miguel
  • Ardanaz, Eva
  • Micó-Pérez, Rafael Manuel
  • Fernandez-Martinez, Nicolás Francisco
  • Rodríguez-Pérez, María del Cristo
  • Cenarro, Ana
  • Calle-Pascual, Alfonso L.
  • Marrugat, Jaume
The CORDELIA Study (Collaborative Cohorts Reassembled Data to Study Mechanisms and Long-term Incidence of Chronic Diseases) combines 35 Spanish population cohorts to investigate the clinical, environmental, genetic, and omics determi-nants of cardiovascular disease in the Southern European population. It aims to conduct the largest genome-wide association study to date on cardiovascular disease in this population, improve predictions of cardiovascular incidence using genomic and clinical data, and identify subgroups that would benefit most from targeted pharmacological and lifestyle interven-tions. CORDELIA includes 196,632 individuals (ages 18–84, 54% female, 96% born in Spain, 20% with higher education, recruited from 1989 to 2020, with follow-up periods ranging from 5 to 30 years), with DNA samples available for 117,342 participants (60%). Of the participants, 24% were current smokers, 43% hypertensive, 11% diabetic, 15% medicated with lipid-lowering drugs, 44% overweight, and 27% obese. If not already available, genotyping is being performed using the Axiom™ Spain Biobank array (~ 750,000 variants, including 115,000 specific and 50,000 rare functional variants from the Spanish population). The cohort also includes incident events (coronary heart disease, stroke, heart failure, peripheral artery disease, hypertension, diabetes); date and cause of death; and harmonized data on risk factors (body mass index, waist circumference, lipid profile, blood pressure, glucose, creatinine), lifestyle (smoking, physical activity, diet, alcohol), and socioeconomic status. 99,019 participants (50%) also provide plasma samples. CORDELIA will significantly contribute to understanding the complex interplay of risk factors contributing to cardiovascular disease and advance the fields of precision medicine and public health in Southern European individuals., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease in severe obesity and concordance between Invasive (Biopsy) and noninvasive (OWLiver®) diagnoses

  • Navarro Masip, Èlia
  • Mestres Petit, Núria
  • Salinas-Roca, Blanca
  • Herrerías, Fernando
  • Vilardell, Felip
  • de la Fuente, Mari Cruz
  • Pallares, Judit
  • Santamaría Gómez, Maite
  • Zorzano-Martínez, Marta
  • Sánchez, Enric
  • Matias-Guiu, Xavier
  • López-Cano, Carolina
  • Soler, Ana Gloria
  • León-Mengíbar, Josep
  • Bueno, Marta
  • Lecube, Albert
Introduction: Nonalcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is an escalating health concern linked to obesity and type 2 diabetes. Despite liver biopsy being the gold standard, its invasiveness underscores the need for noninvasive diagnostic methods. Methods: A cross-sectional study was performed to assess MASLD using the noninvasive OWLiver® serum lipidomics test in a cohort of 117 patients with severe obesity undergoing bariatric surgery, comparing outcomes with liver biopsy. Exclusions (n = 24) included insufficient data, liver disease etiology other than MASLD, corticosteroid treatment, excessive alcohol consumption, low glomerular filtration rate, and declination to participate. Comprehensive laboratory tests, demographic assessments, and liver biopsies were performed. Serum metabolites were analyzed using OWLiver®, a serum lipidomic test that discriminates between healthy liver, steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and MASH with fibrosis ≥2 by means of three algorithms run sequentially. Results: Liver biopsy revealed a MASLD prevalence of 95.7%, with MASH present in 28.2% of cases. OWLiver® demonstrated a tendency to diagnose more severe cases. Body mass index (BMI), rather than the presence of type 2 diabetes, emerged as the sole independent factor linked to the probability of concordance. Therefore, the all-population concordance of 63.2% between OWLiver® and liver biopsy notably raised to 77.1% in patients with a BMI <40 kg/m2. These findings suggest a potential correlation between lower BMI and enhanced concordance between OWLiver® and biopsy. Conclusion: This study yields valuable insights into the concordance between liver biopsy and the noninvasive serum lipidomic test, OWLiver®, in severe obesity. OWLiver® demonstrated a tendency to amplify MASLD severity, with BMI values influencing concordance. Patients with BMI <40 kg/m2 may derive optimal benefits from this noninvasive diagnostic approach., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors

  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Valassi, Elena|||0000-0002-3864-0105
  • Serra, Guillermo
  • Salinas, Isabel
  • Xifra, Gemma
  • Casano-Sancho, Paula
  • Carrato, Cristina|||0000-0002-1953-8287
  • Biagetti, Betina|||0000-0002-8837-4343
  • Sesmilo, Gemma|||0000-0001-5022-1344
  • Marcos-Ruiz, Jennifer
  • Rodriguez-Lloveras, Helena|||0000-0002-6669-3087
  • Rueda-Pujol, Anna|||0000-0002-6671-3180
  • Aulinas, Anna|||0000-0002-1205-7114
  • Blanco, Alberto
  • Hostalot, Cristina|||0000-0002-1935-0524
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Muñoz, Fernando
  • Rico, Marta
  • Ibáñez-Domínguez, Javier
  • Cordero Asanza, Esteban|||0000-0003-0464-3014
  • Webb, S. M.|||0000-0001-7052-6436
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Different medical therapies have been developed for pituitary adenomas. However, Non-Functioning Pituitary Neuroendocrine Tumors (NF-PitNET) have shown little response to them. Furthermore, epithelial-mesenchymal transition (EMT) has been linked to resistance to medical treatment in a significant number of tumors, including pituitary adenomas. We aimed to evaluate the expression of EMT-related markers in 72 NF-PitNET and 16 non-tumoral pituitaries. To further explore the potential usefulness of medical treatment for NF-PitNET we assessed the expression of somatostatin receptors and dopamine-associated genes. We found that SNAI1, SNAI2, Vimentin, KLK10, PEBP1, Ki-67 and SSTR2 were associated with invasive NF-PitNET. Furthermore, we found that the EMT phenomenon was more common in NF-PitNET than in GH-secreting pituitary tumors. Interestingly, PEBP1 was overexpressed in recurrent NF-PitNET, and could predict growth recurrence with 100% sensitivity but only 43% specificity. In parallel with previously reported studies, SSTR3 is highly expressed in our NF-PitNET cohort. However, SSTR3 expression is highly heterogeneous among the different histological variants of NF-PitNET with very low levels in silent corticotroph adenomas. NF-PitNET showed an enhanced EMT phenomenon. SSTR3 targeting could be a good therapeutic candidate in NF-PitNET except for silent corticotroph adenomas, which express very low levels of this receptor. In addition, PEBP1 could be an informative biomarker of tumor regrowth, useful for predictive medicine in NF-PitNET.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

  • Ruiz-Janer, Sabina|||0000-0002-8073-9504
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Biagetti, Betina|||0000-0002-8837-4343
  • Venegas, Eva
  • Cámara, Rosa|||0000-0002-3289-3400
  • García Centeno, Rogelio
  • Gálvez, María-Angeles
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Maraver, Silvia
  • González, Inmaculada
  • Abellán-Galiana, Pablo|||0000-0003-1221-3946
  • Trincado, Pablo
  • Herrera, Mayte T.
  • Olvera, Pilar
  • Xifra, Gemma
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Serra-Soler, Guillermo
  • Azriel, Sharona
  • García, Lourdes
  • Carvalho, Davide|||0000-0002-3156-3741
  • Jordà, Mireia|||0000-0003-3709-1850
  • Valassi, Elena|||0000-0002-3864-0105
  • Puig, Josep|||0000-0003-2791-6599
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Objective: Hyperintensity signal in T2-weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real-life clinical practice. Design, Patients and Measurements: Retrospective multicentre study including acromegaly patients treated with pasireotide. Adenoma T2-weighted MRI signal at diagnosis was qualitatively classified as iso-hyperintense or hypointense. Insulin-like growth factor (IGF-I), growth hormone (GH) and tumour volume reduction were assessed after 6 and 12 months of treatment and its effectiveness evaluated according to baseline MRI signal. Hormonal response was considered 'complete' when normalization of IGF-I levels was achieved. Significant tumour shrinkage was defined as a volume reduction of ≥25% from baseline. Results: Eighty-one patients were included (48% women, 50 ± 1.5 years); 93% had previously received somatostatin receptor ligands (SRLs) treatment. MRI signal was hypointense in 25 (31%) and hyperintense in 56 (69%) cases. At 12 months of follow-up, 42/73 cases (58%) showed normalization of IGF-I and 37% both GH and IGF-I. MRI signal intensity was not associated with hormonal control. 19/51 cases (37%) presented a significant tumour volume shrinkage, 16 (41%) from the hyperintense group and 3 (25%) from the hypointense. Conclusions: T2-signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF-I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Valassi, Elena|||0000-0002-3864-0105
  • Hernández García, Marta|||0000-0003-1237-298X
  • Biagetti, Betina|||0000-0002-8837-4343
  • Giménez-Palop, Olga|||0000-0002-4526-6342
  • Martínez, Silvia
  • Carrato, Cristina|||0000-0002-1953-8287
  • Pons, Laura|||0000-0003-0784-4110
  • Villar Taibo, Rocío
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Blanco Carrera, Concepción|||0000-0001-7171-9459
  • Simón, Inmaculada
  • Simó-Servat, Andreu|||0000-0002-1092-1327
  • Xifra, Gemma
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pavón, Isabel
  • García Centeno, Rogelio
  • Zavala, Roxana
  • Hanzu, Felicia A.|||0000-0002-2399-4023
  • Mora, Mireia|||0000-0002-5887-5016
  • Aulinas, Anna|||0000-0002-1205-7114
  • Vilarrasa, Nuria|||0000-0003-3188-1990
  • Librizzi, Soledad
  • Calatayud, María|||0000-0002-6737-7289
  • de Miguel, Paz
  • Álvarez-Escolá, Cristina|||0000-0002-4684-1652
  • Picó Alfonso, Antonio M.|||0000-0002-7549-7563
  • Sampedro Núñez, Miguel Antonio
  • Salinas, Isabel
  • Fajardo-Montañana, Carmen|||0000-0002-0784-0761
  • Cámara, Rosa|||0000-0002-3289-3400
  • Bernabeu Morón, Ignacio|||0000-0001-8421-7394
  • Jordà, Mireia|||0000-0003-3709-1850
  • Webb, S. M.|||0000-0001-7052-6436
  • Marazuela, Mónica|||0000-0003-1158-9618
  • Puig Domingo, Manuel|||0000-0002-6744-7195
We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2). A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was ≥3SDS, were considered non-responders. The 2 hours GH value (GH) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. In all, 30 patients were responders and 17 were non-responders. GH was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 ± 4.2 vs 3.3 ± 2.1; p=0.01). The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly

  • Marqués Pamies, Montserrat|||0000-0001-6391-5070
  • Gil Ortega, Joan|||0000-0003-1030-9119
  • Jordà, Mireia|||0000-0003-3709-1850
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Background and Aims: Predictors of first-generation somatostatin receptor ligands (fgSRLs) response in acromegaly have been studied for over 30 years, but they are still not recommended in clinical guidelines. Is there not enough evidence to support their use? This systematic review aims to describe the current knowledge of the main predictors of fgSRLs response and discuss their current usefulness, as well as future research directions. Methods: A systematic search was performed in the Scopus and PubMed databases for functional, imaging, and molecular predictive factors. Results: A total of 282 articles were detected, of which 64 were included. Most of them are retrospective studies performed between 1990 and 2023 focused on the predictive response to fgSRLs in acromegaly. The usefulness of the predictive factors is confirmed, with good response identified by the most replicated factors, specifically low GH nadir in the acute octreotide test, T2 MRI hypointensity, high Somatostatin receptor 2 (SSTR2) and E-cadherin expression, and a densely granulated pattern. Even if these biomarkers are interrelated, the association is quite heterogeneous. With classical statistical methods, it is complex to define reliable and generalizable cut-off values worth recommending in clinical guidelines. Machine-learning models involving omics are a promising approach to achieve the highest accuracy values to date. Conclusions: This survey confirms a sufficiently robust level of evidence to apply knowledge of predictive factors for greater efficiency in the treatment decision process. The irruption of artificial intelligence in this field is providing definitive answers to such long-standing questions that may change clinical guidelines and make personalized medicine a reality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RE-START, Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

  • Romero del Rincón, Celia|||0000-0002-0339-6616
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
  • Quintas, Sonia|||0000-0003-0622-8228
  • Garcia Azorin, David|||0000-0002-3132-1064
  • Fernández-Lázaro, Iris|||0009-0004-2544-5206
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • González Osorio, Yésica|||0000-0003-1461-9798
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • González Oria, Carmen
  • Sánchez Rodríguez, Norberto
  • Iglesias Díez, Fernando
  • Echavarría Íñiguez, Ana|||0000-0001-7038-2911
  • Gil Luque, Sendoa
  • Huerta, Mariano|||0000-0003-0181-5335
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Velasco Juanes, Fernando
  • Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
  • Echeverría, Amaya|||0000-0001-9225-5323
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Jaimes Sánchez, Alex
  • Gómez García, Andrea
  • Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
  • Belvís, Roberto|||0000-0002-2137-180X
  • Navarro Pérez, María Pilar|||0000-0001-6370-218X
  • García-Moncó, Juan Carlos
  • Álvarez Escudero, María Rocío
  • Montes, Nuria
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Huntingtin CAG repeats in neuropathologically confirmed tauopathies, Novel insights

  • Pérez-Oliveira, Sergio|||0000-0002-3292-0501
  • Castilla-Silgado, Juan|||0000-0002-6266-8247
  • Painous, Cèlia|||0000-0002-7027-3093
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Corte, Daniela
  • Tomás-Zapico, Cristina|||0000-0001-7823-0410
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Muñoz García, José Esteban|||0000-0002-0986-1291
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Balasa, Mircea|||0000-0002-1795-4228
  • Aragonès, Gemma
  • García-González, Pablo|||0000-0003-0125-5403
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Pastor, Pau|||0000-0002-7493-8777
  • Casa-Fages, Beatriz de la|||0000-0003-0486-3308
  • Rábano, Alberto|||0000-0001-9320-6566
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Molina-Porcel, L.
  • Alvarez, Victoria|||0000-0002-1916-2523
Previous studies have suggested a relationship between the number of CAG triplet repeats in the HTT gene and neurodegenerative diseases not related to Huntington's disease (HD). This study seeks to investigate whether the number of CAG repeats of HTT is associated with the risk of developing certain tauopathies and its influence as a modulator of the clinical and neuropathological phenotype. Additionally, it aims to evaluate the potential of polyglutamine staining as a neuropathological screening. We genotyped the HTT gene CAG repeat number and APOE-ℰ isoforms in a cohort of patients with neuropathological diagnoses of tauopathies (n=588), including 34 corticobasal degeneration (CBD), 98 progressive supranuclear palsy (PSP) and 456 Alzheimer's disease (AD). Furthermore, we genotyped a control group of 1070 patients, of whom 44 were neuropathologic controls. We identified significant differences in the number of patients with pathological HTT expansions in the CBD group (2.7%) and PSP group (3.2%) compared to control subjects (0.2%). A significant increase in the size of the HTT CAG repeats was found in the AD compared to the control group, influenced by the presence of the Apoliprotein E (APOE)-ℰ4 isoform. Post-mortem assessments uncovered tauopathy pathology with positive polyglutamine aggregates, with a slight predominance in the neostriatum for PSP and CBD cases and somewhat greater limbic involvement in the AD case. Our results indicated a link between HTT CAG repeat expansion with other non-HD pathology, suggesting they could share common neurodegenerative pathways. These findings support that genetic or histological screening for HTT repeat expansions should be considered in tauopathies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.